JCML clinical trials at UCSF

1 research study open to eligible people

JCML is juvenile myelomonocytic leukemia, a rare type of blood cancer in children. UCSF studies how trametinib and azacitidine work together. This clinical trial checks if these drugs are safe and effective for those with newly diagnosed JCML.

Showing trials for

  • Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

    open to eligible people ages 1 month to 21 years

    This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-risk JMML patients will receive trametinib, azacitidine, fludarabine, and cytarabine.

    San Francisco, California and other locations

Last updated: